- Home
- Available Courses
Most Recent Courses
Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021
- 0.50 AMA PRA Credit
Published:
Learning objectives
- Identify patients likely to benefit from invasive procedures versus pharmacological treatment
- Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
ADVANCES IN IMAGING: OPTIMISING MR AND CT IN DAILY PRACTICE
- 2.00 EBAC
Published:
Learning objectives
- Interpret existing clinical and meta data for use of pre-procedural, image-aided ablation in ventricular arrhythmias
- Identify where pre-procedural imaging may complement the current ablation workflow in ventricular arrhythmias
- Recall the clinical benefits of quantitative, MRI-based approaches to evaluate ischaemia
- Apply quantitative CMR imaging to complement existing procedural workflows in revascularisation procedures
TAVI Haemodynamics and Outcomes: Are We Measuring Appropriately?
- 1.00 EBAC
Published:
Learning objectives
- Describe how echo-based and catheter-based measurements differ when measuring haemodynamics post-TAVI
- Recall common factors impacting the accuracy of haemodynamic measurements and how they can be controlled
- Evaluate the relationship between TAVI and clinical outcomes based on clinical data
- Summarise how haemodynamic monitoring can be adopted post-TAVI
P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients
- 1.00 EBAC
Published:
Learning objectives
- Recall the supportive evidence underpinning recommended antiplatelet approaches in individuals with unknown coronary anatomy, including choice of therapy, duration, timing and loading doses
- Compare the design of different clinical trials that have influenced antiplatelet therapy choice in NSTE-ACS patients who proceed to PCI
- Apply trial data and clinical guidelines on the use of antiplatelet therapy in patients undergoing revascularisation to a surrogate patient case
Hypertrophic Cardiomyopathy in Review: Highlights 2019-2021
- 0.25 AMA PRA Credit
Published:
Learning objectives
- Recall the efficacy and safety of existing HCM treatments
- Summarize results from ongoing trials with experimental treatments
Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice
- 1.00 MMA
Published:
Learning objectives
- Understand the latest ARNI data in HFpEF and HFrEF
- Understand how emerging data relates to current practice in Malaysia
- Apply current understanding of ARNI therapy in appropriate heart failure patients
Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme
- 1.00 MMA
Published:
Learning objectives
- Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
- List the main clinical implications of cardiac remodelling.
- Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
- Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
- Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
- Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
- 1.00 EBAC
Published:
Learning objectives
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
- Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
- Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
- Assess the interrelationships linking diabetes, HF and CVD.
- Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
- Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
Dual antiplatelet therapy for acute stroke and TIA
- 1.00 EBAC
Published:
Learning objectives
- To highlight the continued high unmet need for strategies to prevent stroke or death for patients experiencing acute stroke or TIA
- To outline the guidelines on the use of dual antiplatelet therapy for patients presenting with acute stroke or TIA
- To examine recent evidence from clinical trials on novel strategies for improving outcomes for patients presenting with acute stroke or TIA and how these data and insights can be applied in clinical practice